Long‐term Hypotensive Effect of Atenolol (ICI 66.082), a New β‐adrenergic Blocking Agent

12 January 1976

journal article
research article
Published by Wiley in Acta Medica Scandinavica

Vol. 199 (1-6) , 257-262
https://doi.org/10.1111/j.0954-6820.1976.tb06729.x

Abstract

This is a report from an on-going multicenter trial in Sweden, in which 117 hypertensive patients were treated with a new cardioselective .beta.-adrenergic blocking agent, atenolol (ICI 66.082, Tenormin) for an average of 6 mo. (range 2-21). Statistically significant reductions of BP [blood pressure] were observed, recumbent by 29/19 mmHg (p < 0.0001) and standing by 28/18 mmHg (p < 0.0001). Few and comparatively mild side-effects were seen.

This publication has 13 references indexed in Scilit:

Letter: Skin reactions to beta-blockers.
BMJ, 1974
Letter: Skin reactions to practolol.
BMJ, 1974
Management of severe hypertension
The American Journal of Cardiology, 1973
INITIAL CLINICAL EXPERIENCE WITH I.C.I. 66.082, A NEW β‐ADRENERGIC BLOCKING AGENT, IN HYPERTENSION.
Acta Medica Scandinavica, 1973
Propranolol in hypertension: A study of long-term therapy, 1964–1970
American Heart Journal, 1972
Propranolol therapy in essential hypertension
American Heart Journal, 1972
Treatment of Hypertension with Propranolol
BMJ, 1969
EFFECT OF PROPRANOLOL IN MILD HYPERTENSION
The Lancet, 1966
Use of Propranolol (Inderal) in Treatment of Hypertension
BMJ, 1964